Oaktree Specialty Lending Corporation (OCSL)
NASDAQ: OCSL · Real-Time Price · USD
11.34
-0.12 (-1.05%)
Mar 9, 2026, 2:08 PM EDT - Market open

Company Description

Oaktree Specialty Lending Corporation is a business development company.

The fund specializing in investments in middle market, bridge financing, first and second lien debt financing, unsecured and mezzanine loan, mezzanine debt, senior and junior secured debt, expansions, sponsor-led acquisitions, preferred equity, and management buyouts in small and mid-sized companies.

It seeks to invest in education services, business services, retail and consumer, healthcare, manufacturing, food and restaurants, construction and engineering.

The firm also seeks investment in media, advertising sectors, software, IT services, pharmaceuticals, biotechnology, real estate management and development, chemicals, machinery, and internet and direct marketing retail sectors.

It invests between $5 million to $75 million principally in the form of one-stop, first lien, and second lien debt investments, which may include an equity co-investment component in companies.

The firm invest in companies having enterprise value between $20 million and $150 million and EBITDA between $3 million and $50 million.

The fund has a hold size of up to $75 million and may underwrite transactions up to $100 million. It primarily invests in North America.

The fund seeks to be a lead investor in its portfolio companies.

Oaktree Specialty Lending Corporation
Oaktree Specialty Lending logo
Country United States
Founded 2007
IPO Date Jun 12, 2008
Industry Asset Management
Sector Financials
Employees 17
CEO Armen Panossian

Contact Details

Address:
333 South Grand Avenue, 28th Floor
Los Angeles, California 90071
United States
Phone 213 830 6300
Website oaktreespecialtylending.com

Stock Details

Ticker Symbol OCSL
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001414932
CUSIP Number 67401P108
ISIN Number US67401P4054
Employer ID 26-1219283

Key Executives

Name Position
Armen Panossian J.D. Chief Executive Officer and Co-Chief Investment Officer
Mathew M. Pendo President
Dr. Aman Kumar M.D. Managing Director and Co-Portfolio Manager of Life Sciences Direct Lending
Christopher McKown Chief Financial Officer and Treasurer
Brett McKeone Chief Operating Officer
Raghav Khanna Co-Chief Investment Officer
Dane Kleven Senior Vice President and Head of Investor Relations
Mary Gallegly J.D. MD,General Counsel and Secretary
Ashley Pak Chief Compliance Officer
Sandeep Kumar Khorana Managing Director of Origination

Latest SEC Filings

Date Type Title
Mar 4, 2026 8-K Current Report
Feb 4, 2026 8-K Current Report
Feb 4, 2026 10-Q Quarterly Report
Feb 2, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jan 23, 2026 N-2ASR Filing
Jan 16, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jan 16, 2026 DEF 14A Other definitive proxy statements
Jan 8, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jan 8, 2026 DEF 14A Other definitive proxy statements
Dec 22, 2025 PRE 14A Other preliminary proxy statements